NC
INFI

Northpointe Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Northpointe Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-528,739
Closed -$1.43M – 195
2018
Q3 		$1.43M Buy
+528,739
New +$1.09M 0.21% 161

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Northpointe Capital's INFI Position: Q4 2018 in Review

Northpointe Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2018, closing a stake of 528,739 shares — an estimated $1.43M sold.

Northpointe Capital first reported a position in INFI in Q3 2018 and held it in 1 quarter. The position peaked at $1.43M in Q3 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q4 2018.

  • Northpointe Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Northpointe Capital sold 528,739 Infinity Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1.43M.
  • Northpointe Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Northpointe Capital's Infinity Pharmaceuticals, Inc. position peaked at $1.43M in Q3 2018.
  • 64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2018.

Based on Northpointe Capital's 13F filing for Q4 2018, filed 24 Jan 2019.